Elin Forsgren

PhD student at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Ingrid Glimelius

E-mail:: elin.forsgren@igp.uu.se
Visiting address:: Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Postal address:: Akademiska sjukhuset, ingång 100/101
751 85 Uppsala

Download contact information for Elin Forsgren at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Ingrid Glimelius

Short presentation

Elin Forsgren is a physician and PhD-student with a clinical and scientific focus on hematological diseases, especially lymphoid malignancies. Her overall aim is to study risk and prognostic factors for malignant lymphoma with focus on mantle cell lymphoma. With her research she wants to understand how personal factors, such as age, comorbidities and socioeconomic status can affect biological factors as well as prognosis.

Publications

Recent publications

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

Forsgren, Elin; Jorgensen, Rasmus R. K.; Bentzen, Hans; Riise, Jon et al.

Part of HemaSphere, 2025
- DOI for Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
- Download full text (pdf) of Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers

Forsgren, Elin; Ekberg, Sara; Smedby, Karin E.; Nylund, Patrick et al.

Part of British Journal of Haematology, p. 1794-1803, 2024
- DOI for Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers
- Download full text (pdf) of Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers

All publications

Articles in journal

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial

Forsgren, Elin; Jorgensen, Rasmus R. K.; Bentzen, Hans; Riise, Jon et al.

Part of HemaSphere, 2025
- DOI for Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
- Download full text (pdf) of Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers

Forsgren, Elin; Ekberg, Sara; Smedby, Karin E.; Nylund, Patrick et al.

Part of British Journal of Haematology, p. 1794-1803, 2024
- DOI for Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers
- Download full text (pdf) of Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers